Lenvatinib
Reading tools
Lenvatinib (Lenvima®), which received FDA approval on 13 February 2015, is used particularly in recurrent disease spread to distant tissues (metastatic) and unresponsive to radioactive iodine (atomic) treatment, in patients with thyroid cancer . By inhibiting the functioning of RTK (receptor tyrosine kinase) on the cell surface, Lenvatinib prevents cancer growth and the new blood vessel formation necessary for spread to distant tissues.
Its most common side effects are high blood pressure, fatigue, diarrhea, joint and muscle pain and reduced appetite.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.